2020 DIA China Annual Meeting

In recent years, the biopharmaceutical industry has entered a rapid stage of development with the support of national policies, capital market and large number of talents returning. COVID-19 in 2020 has raised people’s attention to the biopharmaceutical industry to a new level. However, there are still many challenges behind the rapid development. For example, as more and more antibody drugs enter the late clinical and commercial production stages, it is urgent to achieve further cost reduction and efficiency enhancement in order to large-scale access to patients. As the future direction of biopharmaceutical production technology, continuous manufacturing is undoubtedly one of the most suitable directions for promoting. At present, Johnson & Johnson, Lilly, GSK, Amgen have all carried out continuous manufacturing technology. Recently, Biosana Pharma has successfully completed phase I clinical trial for Omalizumab biosimilar using a full continuous manufacturing process. At the same time, some well-known local biopharmaceutical enterprises in China, such as WuXi Biologics and Henlius, have also taken the lead in the development of continuous manufacturing. This session will share and discuss future trends, applications and regulations, as well as challenges and opportunities for continuous manufacturing.